Create a narrative

Invivyd Community

NasdaqGM:IVVD Community

1 Narratives written by author
0 Comments on narratives written by author
74 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Key Takeaways Expansion of a skilled commercial team and new therapeutic programs positions Invivyd for broader market adoption, revenue growth, and reduced product concentration risk. Financial discipline and evolving regulatory support enhance sustainability, lower risk, and may fast-track product approvals and recurring revenue opportunities.

US$2.93

FV

80.2% undervalued

96.33%

Revenue growth p.a.

0

0

34

Updated